Business Context and Reporting Period
This Form 8-K Current Report was filed by Coherus BioSciences, Inc. on April 14, 2020, covering events occurring on April 13, 2020. The filing addresses amendments to material debt agreements and provides preliminary unaudited financial results for the first quarter of 2020.
Key Financial Metrics and Preliminary Results
The Company provided preliminary unaudited estimates for the first quarter of 2020, noting that final results may vary as closing procedures are incomplete.
- Net Product Revenue: Estimated between $115.0 million and $117.5 million.
- Net Income: Estimated between $33.5 million and $38.0 million.
- Unit Growth: UDENYCA® saw 7% unit growth in the last four weeks of March 2020 compared to the previous four weeks.
- Debt Covenants: Amendments allow the Company to incur Convertible Bond Indebtedness up to the greater of $230.0 million or 20% of market capitalization.
The filing does not provide specific values for cash flow, operating margins, total debt balance, or liquidity ratios beyond the debt covenant thresholds.
Material Changes Versus Prior Period
Compared to the first quarter of 2019, the Company anticipates significant improvements in financial performance:
- Revenue Growth: Net product revenue is expected to increase by 210% to 217% from $37.1 million in Q1 2019.
- Profitability Shift: The Company expects to report a net income of $33.5 million to $38.0 million, a reversal from a net loss of $20.0 million in Q1 2019.
- Contractual Changes: The Note Purchase Agreement was amended to exclude payments under Permitted Bond Hedge Transactions from the definition of Restricted Payments. The Credit Agreement was amended to permit additional convertible bond indebtedness.
Outlook, Risks, and Management Commentary
Management Commentary: Management noted that Q1 2020 results reflect a "modest" impact from COVID-19 in March 2020. Despite the pandemic, the pegfilgrastim class showed 6% year-over-year unit growth.
Risks and Contingencies: The Company added a supplemental risk factor regarding the COVID-19 pandemic, highlighting potential disruptions including:
- Decreased sales of UDENYCA® due to strained healthcare resources and travel restrictions limiting sales team efficacy.
- Fewer patients undertaking cancer treatments due to self-isolation or healthcare system strain.
- Supply chain disruptions from third-party contract manufacturers.
- Delays in clinical trials, regulatory reviews, and site initiation.
- Potential negative impact on liquidity and access to capital due to global financial market disruptions.
Unusual Items: The Company closed its headquarters in Redwood City, California, following "shelter-in-place" orders issued in mid-March 2020.
Investor Verification Checklist
- Verify the final audited Q1 2020 financial results against the preliminary ranges provided ($115.0M-$117.5M revenue; $33.5M-$38.0M net income).
- Review the full text of the Second Amendment to the Convertible Note Purchase Agreement (Exhibit 10.1) and the Credit Agreement Amendment (Exhibit 10.2) to understand specific debt covenants.
- Monitor subsequent filings for updates on the duration and severity of COVID-19 impacts on UDENYCA® sales and clinical trial timelines.
- Assess the Company's liquidity position and ability to access capital markets given the stated risks of global financial market disruption.